Constipation, IBS and the 5-HT4 receptor: What role for prucalopride?

Clinical Medicine Insights: Gastroenterology

Volumn 3, Issue , 2010, Pages 21-33

  Sanger, Gareth J ^a   Quigley, Eamonn M M ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Constipation; IBS; Prucalopride

Indexed keywords

CHLORIDE CHANNEL; CHLORIDE ION; CISAPRIDE; DELAYED RECTIFIER POTASSIUM CHANNEL; GUANYLATE CYCLASE C RECEPTOR; LINACLOTIDE; LUBIPROSTONE; MD 01100; PLACEBO; PRUCALOPRIDE; RECEPTOR PROTEIN; SEROTONIN 2B RECEPTOR; SEROTONIN 4 AGONIST; SEROTONIN 4 RECEPTOR; TEGASEROD; UNCLASSIFIED DRUG; VELUSETRAG;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ARTICLE; CARDIOTOXICITY; CHLORIDE TRANSPORT; CHOLINERGIC TRANSMISSION; CHRONIC CONSTIPATION; CHRONIC IDIOPATHIC CONSTIPATION; COLON MOTILITY; COLON RESECTION; CONSTIPATION; DIARRHEA; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EXCRETION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ELECTROCARDIOGRAM; ENTEROCHROMAFFIN CELL; GASTROINTESTINAL MOTILITY; HEMODYNAMICS; HUMAN; IDIOPATHIC CONSTIPATION; INTESTINE INNERVATION; INTESTINE MOTILITY; INTESTINE MUCOSA; INTESTINE MUSCLE; IRRITABLE COLON; NAUSEA; NONHUMAN; OSMOSIS; PROTEIN EXPRESSION; PROTEIN VARIANT; QT PROLONGATION; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; SPONTANEOUS COMPLETE BOWEL MOVEMENT; SUDDEN DEATH; SYMPTOM; TISSUE DISTRIBUTION; UNSPECIFIED SIDE EFFECT; VISCERAL PAIN;

EID: 78650734005     PISSN: 11795522     EISSN: 11795522     Source Type: Journal    
DOI: 10.4137/CGast.S4136     Document Type: Article

References (100)

1. Sanger GJ. Translating 5-HT4 receptor pharmacology. Neurogastroenterol Motil. 2009;21:1235-8.
2. Leclere PG, Prins NH, Schuurkes JA, Lefebvre RA. 5-HT4 receptors located on cholinergic nerves in human colon circular muscle. Neurogastroenterol Motil. 2005;17:366-5.
3. Cellek S, John AK, Thangiah R, et al. 5-HT4 receptor agonists enhance both cholinergic and nitrergic activity in human isolated colon circular muscle. Neurogastroenterol Motil. 2006;18:853-61.
4. Broad J, Boundouki G, Knowles, CH, Sanger GJ. Characterisation of motor nerve responses to electrical feld stimulation in human isolated colon. Gut. 2010;59 Suppl 1:A140.
5. Lefebvre RA, Ferrero S, van Colen I, et al. Infuence of 5-HT4 receptor activation on acetylcholine release in human large intestine with endometriosis. Neurogastroenterol Motil. 2010;22:557-63.
6. Prins NH, Akkermans LM, Lefebvre RA, Schuurkes JA. 5-HT4 receptors on cholinergic nerves involved in contractility of canine and human large intestine longitudinal muscle. Br J Pharmacol. 2000;131:927-32.
7. Kilbinger H, Wolf D. Effects of 5-HT4 receptor stimulation on basal and electrically evoked release of acetylcholine from guinea-pig myenteric plexus. Naunyn Schmiedebergs Arch Pharmacol. 1992;345:270-5.
8. Poole DP, Xu B, Koh SL, et al. Identifcation of neurons that express 5- hydroxytryptamine4 receptors in intestine. Cell Tissue Res. 2006;325: 413-22.
9. McLean PG, Coupar IM, Molenaar P. A comparative study of functional 5-HT4 receptors in human colon, rat oesophagus and rat ileum. Br J P harmacol. 1995;115:47-56.
10. Tam FS, Hillier K, Bunce KT, Grossman C. Differences in response to 5-HT4 receptor agonists and antagonists of the 5-HT4-like receptor in human colon circular smooth muscle. Br J Pharmacol. 1995;115:172-6.
11. Prins NH, Shankley NP, Welsh NJ, et al. An improved in vitro bioassay for the study of 5-HT4 receptors in the human isolated large intestinal circular muscle. Br J Pharmacol. 2000;129:1601-8.
12. Irving HR, Tan YY, Tochon-Danguy N, et al. Comparison of 5-HT4 and 5-HT7 receptor expression and function in the circular muscle of the human colon. Life Sci. 2007;80:1198-205.
13. Sakurai-Yamashita Y, Yamashita K, Yoshimura M, Taniyama K. Differential localization of 5-hydroxytryptamine3 and 5-hydroxytryptamine4 receptors in the human rectum. Life Sci. 2000;66:31-4.
14. Hardcastle J, Hardcastle PT, Redfern JS. Action of 5-hydroxytryptamine on intestinal ion transport in the rat. J Physiol. 1981;320:41-55.
15. - secretion in human jejunal mucosa in vitro via a nonneural pathway at a 5-HT4 receptor. Am J Physiol. 1994;267(3 Pt 1):G357-63.
16. - secretion in human jejunal mucosa. Eur J Pharmacol. 1996;314: 109-14.
17. Borman RA, Burleigh DE. Heterogeneity of 5-HT receptors mediating secretion in the human intestine. Ann NY Acad Sci. 1997;812:224-5.
18. - secretion via afferent neurons and 5-HT4 receptors. Am J Physiol. 1999;277:G515-20.
19. Schwörer H, Ramadori G. Autoreceptors can modulate 5-hydroxytryptamine release from porcine and human small intestine in vitro. Naunyn Schmiedeberg's Arch Pharmacol. 1998;357:548-52.
20. Bockaert J, Roussignol G, Bécamel C, et al. GPCR-interacting proteins (GIPs): nature and functions. Biochem Soc Transactions. 2004;32: 851-5.
21. Coupar IM, Desmond PV, Irving HR. Human 5-HT4 and 5-HTsub7/sub splice variants: Are they important? Curr Neuropharmacol. 2007;5: 224-31.
22. Medhurst AD, Lezoualc'h F, Fischmeister R, Middlemiss DN, Sanger GJ. Quantitative mRNA analysis of fve C-terminal splice variants of the human 5-HT4 receptor in the central nervous system by TaqMan real time RT-PCR. Mol Brain Res. 2001;90:125-34.
23. Mialet J, Berque-Bestal I, Sicsic S, Langlois M, Fischmeister R, Lezoualc'h F. Pharmacological characterization of the human 5-HT4(d) receptor splice variant stably expressed in Chinese hamster ovary cells. Br J Pharmacol. 2000;131:827-35.
24. Briejer MR, Bosmans JP, van Daele P, et al. The in vitro pharmacological profle of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001;423:71-83.
25. + channel and the common T897 poly-morph. Eur J Pharmacol. 2007;554:98-105.
26. Wong BS, Manabe N, Camilleri M. Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation. Clin Exp Gastroenterol. 2010;3:49-56.
27. Kaumann AJ, Levy FO. 5-hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther. 2006;111:674-706.
28. King MV, Marsden CA, Fone KC. A role for the 5-HT1A, 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol Sci. 2008;29: 482-92.
29. De Maeyer JH, Prins NH, Schuurkes JAJ, Lefebvre RA. Differential effects of 5-hydroxytryptamine4 receptor agonists at gastric versus cardiac receptors: An operational framework to explain and quantify organ-specifc behavior. J Pharmacol Exp Ther. 2006;317:955-64.
30. De Maeyer JH, Lefebvre RA, Schuurkes JAJ. Selective desensitization of the 5-HT4 receptor-mediated response in pig atrium but not in the stomach. Br J Pharmacol. 2009;156:362-76.
31. Beattie DT, Armstrong SR, Shaw JP, et al. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity. Naunyn-Schmiedeberg's Arch Pharmacol. 2008;378:139-47.
32. Beattie DT, Smith JAM. Serotonin pharmacology in the gastrointestinal tract. Naunyn-Schmiedeberg's Arch Pharmacol. 2008;377:181-203.
33. Beattie DT, Smith JA, Marquess D, et al. The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004;143:549-60.
34. Ohashi-Doi K, Himaki D, Nagao K, et al. A selective, high affnity 5-HT2B receptor antagonist inhibits visceral hypersensitivity in rats. Neurogastroen-terol Motil. 2010;22:e69-76.
35. O'Mahony SM, Bulmer DC, Coelho AM, et al. 5-HT2B receptors modulate visceral hypersensitivity in a stress-sensitive animal model of brain-gut axis dysfunction. Neurogastroenterol Motil. 2010;22:573-8.
36. Greenwood-van Meerveld B, Venkova K, Hicks G, Dennis E, Crowell MD. Activation of peripheral 5-HT4 receptors attenuates colonic sensitivity to intraluminal distension. Neurogastroenterol Motil. 2000;18:76-86.
37. Bassil AK, Taylor CM, Bolton VJN, et al. Inhibition of colonic motility and defecation by RS-127445 suggests an involvement of the 5-HT2B receptor in rodent large bowel physiology. Br J Pharmacol. 2009;158:252-8.
38. Borman RA, Tilford NS, Harmer DW, et al. 5-HT2B receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro. Br J Pharmacol. 2002;135:1144-51.
39. Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 1958 to 1986. Dig Dis Sci. 1989;34:606-11.
40. Drossman DA, Li Z, Andruzzi E, et al. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig Dis Sci. 1993;38:1569-80.
41. Talley NJ, O'Keefe EA, Zinsmeister AR, et al. Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Gastroenterology. 1992;102:895-901.
42. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology. 2006;130:1480-91.
43. Brandt LJ, Schoenfeld P, Prather CM, Quigley EMM, Schiller LR, Talley NJ. Evidence-Based Position Statement on the Management of Chronic Constipation in North America. Am J Gastroenterol. 2005; 100(Suppl 1):S5-21.
44. Brandt LJ, Chey WD, Schiller LR, et al. American College of Gastroen-terology IBS Task Force. An evidence-based systematic review of the management of irritable bowel syndrome. Am J Gastroenterol. 2009;104: S1-35.
45. Quigley EMM, Bergmann JF, Bytzer P, et al. An evidence-based approach to the management of irritable bowel syndrome in Europe. Eur J Gastroenterol Hepatol. 2007;19(Suppl 1):S1-37.
46. Lin HC, Prather C, Fisher RS, et al. Measurement of gastrointestinal transit. Dig Dis Sci. 2005;50:989-1004.
47. Odunsi ST, Camilleri M. Selected interventions in nuclear medicine: gastrointestinal motor functions. Semin Nucl Med. 2009;39:186-94.
48. von der Ohe MR, Camilleri M. Measurement of small bowel and colonic transit: indications and methods. Mayo Clin Proc. 1992;67:1169-79.
49. Camilleri M, Bharucha AE, di Lorenzo C, et al. American Neurogas-troenterology and Motility Society consensus statement on intraluminal measurement of gastrointestinal and colonic motility in clinical practice. Neurogastroenterol Motil. 2008;20:1269-82.
50. Camilleri M, Hasler WL, Parkman HP, Quigley EM, Soffer E. Measurement of gastrointestinal motility in the GI laboratory. Gastroenterology. 1998;115: 747-62.
51. Quigley EM. Current concepts of the irritable bowel syndrome. Scand J Gastroenterol Suppl. 2003:1-8.
52. McKee DP, Quigley EMM. Intestinal motility in irritable bowel syndrome: Is IBS a motility disorder? Part 1: Defnition of IBS and colonic motility. Dig Dis Sci. 1993;38:1761-72.
53. Bouin M, Plourde V, Boivin M, et al. Rectal distension testing in patients with the irritable bowel syndrome: sensitivity, specifcity, and predictive values of pain sensory thresholds. Gastroenterology. 2002;122:1771-7.
54. Sanger GJ, Alpers D. Development of drugs for gastrointestinal motor disorders: Translating science to clinical need. Neurogastroenterol Motil. 2008:20:177-84.
55. Ambizas EM, Ginzburg R. Lubiprostone: a chloride channel activator for treatment of chronic constipation. Ann Pharmacother. 2007;41:957-64.
56. Bassil AK, Borman RA, Jarvie EM, et al. Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol. 2008;154:126-35.
57. McKeage K, Plosker GL, Siddiqui MA. Lubiprostone. Drugs. 2006;66: 873-9.
58. Bouras EP, Camilleri M, Burton DD, McKinzie S. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut. 1999;44:682-686.
59. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology. 2001;120:354-60.
60. Emmanuel AV, Kamm MA, Roy AJ, Antonelli K. Effect of a novel proki-netic drug, R093877, on gastrointestinal transit in healthy volunteers. Gut. 1998;42:511-516.
61. Poen AC, Felt-Bersma RJ, van Dongen PA, Meuwissen SG. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther. 1999;13: 1493-1497.
62. Sloots CE, Poen AC, Kerstens R, et al. Effects of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation. Aliment Pharmacol Ther. 2002;16:759-767.
63. Emmanuel AV, Roy AJ, Nicholls TJ, Kamm MA. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther. 2002;16:1347-1356.
64. De Schryver AM, Andriesse GI, Samsom M, et al. The effects of the spe-cifc 5HT(4) receptor agonist, prucalopride, on colonic motility in healthy volunteers. Aliment Pharmacol Ther. 2002;16:603-612.
65. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008; 358:2344-2354.213.
66. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the eff-cacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29:315-328. 214.
67. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfed with laxatives. Gut. 2009;58:357-365.
68. Dubois D, Gilet H, Viala-Danten M, Tack J. Psychometric performance and clinical meaningfulness of the Patient Assessment of Constipation-Quality of Life questionnaire in prucalopride (RESOLOR) trials for chronic constipation. Neurogastroenterol Motil. 2010;22:e54-63.
69. Müller-Lissner S, Rykx A, Kerstens R, Vandeplassche L. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil. 2010;22:991-998.
70. Coremans G, Kerstens R, de Pauw M, Stevens M. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion. 2003;67:82-89.
71. Sloots CE, Rykx A, Cools M, Kerstens R, de Pauw M. Effcacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55:2912-2921.
72. Krogh K, Jensen MB, Gandrup P, et al. Effcacy and tolerability of prucalopride in patients with constipation due to spinal cord injury. Scand J Gastroenterol. 2002;37:431-436.
73. Boeckxstaens GE, Bartelsman JF, Lauwers L, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol. 2002;97:194-197.
74. + channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol Heart Circ Physiol. 1997;273:H2534-H2538.
75. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm051284.htm (Accessed 2010 Nov 19th).
76. Loughlin J, Quinn S, Rivero E, et al. Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study. J Cardiovasc Pharmacol Ther. 2010;15:151-7.
77. Serebruany VL, Mouelhi ME, Pfannkuche HJ, Rose K, Marro M, Angiolillo DJ. Investigations on 5-HT4 Receptor Expression and Effects of Tegaserod on Human Platelet Aggregation In Vitro. Am J Ther. 2010;17: 543-52.
78. + channel. J Pharmacol Exp Ther. 2001;299(3):1007-12.
79. Boyce M, Kerstens R, Beyens G, Ausma J, Vandeplassche L. Cardiovascular safety of prucalopride in healthy subjects: results from two randomized, double-blind, placebo-controlled, cross-over trials. Gastroenterology. 2009;136(Suppl 1): T1265.
80. ®) in patients with chronic constipation: Pooled data from three pivotal phase III studies. Gastroenterology. 2008;134:A530-1.
81. Camilleri M, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil. 2009;21:1256-e117.
82. De Maeyer JH, Lefebvre RA, Schuurkes JAJ. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008;20:99-112.
83. Sanger GJ. 5-Hydroxytryptamine and the gastrointestinal tract: Where next? Trends Pharmacol Res. 2008;29:465-71.
84. Camilleri M, Vazquez-Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5-HT4 receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil. 2007;19:30-8.
85. Smith JAM, Beattie DT, Marquess D, Shaw J-P, Vickery RG, Humphrey PPA. The in vitro pharmacological profle of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity. Naunyn-Schmiedeberg's. Arch Pharmacol. 2008;378:125-37.
86. Goldberg M, Li Y-P, Johanson JF, et al. Clinical trial: the effcacy and toler-ability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation-a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther. 2010; 32:1102-12.
87. Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010;86:760-5.
88. Krause G, Bayerl A, Heim JM, et al. Distribution of membrane bound gua-nylyl cyclases in human intestine. Gut. 1994;35:1250-7.
89. Nakazato M. Guanylin family: new intestinal peptides regulating electrolyte and water homeostasis. J Gastroenterol. 2001;36:219-25.
90. Forte LR. Guanylin regulatory peptides: structures, biological activities mediated by cyclic GMP and pathobiology. Regul Pept. 1999;81:25-39.
91. Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil. 2010;22:312-e84.
92. Andresen V, Camilleri M, Busciglio IA, et al. Effects of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology. 2007;133:761-8.
93. Johnston JM, MacDougall JE, Lavins BJ, et al. Linaclotide signifcantly improved abdominal pain/discomfort and global assessments in adults with irritable bowel syndrome with constipation. Neurogastroenterol Motil. 2008;20:13 (abstract).
94. Brejer MR, Akkermans LMA, Schuurkes JAJ. Gastrointestinal prokinetic benzamides: the pharmacology underlying stimulation of motility. Pharmacol Rev. 1995;47:631-51.
95. Mine Y, Yoshikawa, Oku S, Nagai R, Yoshida N, Hosoki K. Comparison of Effect of Mosapride Citrate and Existing 5-HT4 Receptor Agonists on Gastrointestinal Motility In Vivo and In Vitro. J Pharmacol Exp Ther. 1997;283:1000-8.
96. De Ponti F, Pharmacology of serotonin: What a clinician should know. Gut. 2004;53:1520-35.
97. Yoshida N, Omoya H, Kato S, Ito T. Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Arzneimittelforschung. 1993;43:1078-83.
98. Schiller LR, Johnson DA. Balancing drug risk and beneft: toward refning the process of FDA decisions affecting patient care. Am J Gastroenterol. 2008;103:815-9.
99. + channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol. 1997;273:H2534-8.
100. http://www.drugs.com/clinical_trials/results-renzapride-phase-iii-clinical trial-4052.html